Make An Appointment Make A Payment Event Registration
Make an appointment

Ana Maria Corregidor, M.D.

Ana Maria Corregidor, M.D.

Dr. Corregidor joins us after completing her Transplant/ Hepatology Fellowship at the MAYO Clinic in Jacksonville. In addition to her special training in Liver diseases, Ana completed a fellowship in Gastroenterology at the University of Florida. She has a special interest in pre and post liver transplant evaluation and management. Dr. Corregidor is the Medical Director of Borland-Groover Clinic’s Liver Center, and is active in several clinical trials investigating new drugs in the treatment of Hepatitis C and B, and other liver diseases. In addition, Dr. Corregidor performs colonoscopy and upper endoscopy.

Office locations

Southside Office

Practicing since

1991

Certifications

  • Board Certified - Transplant and Hepatology, 2010
  • Board Certified - Gastroenterology, 2004
  • Board Certified - Internal Medicine, 1998
  • ECFMG, 1995
  • USMLE: (Step I, II, III), 1993 - 1997

National Provider Identifier

1306842810

Licensure

Florida

Communicate with your physician’s staff through My BGC Health.

Professional Clinical Positions

Professional Clinical Positions
2004 - Present Director of Hepatology - Liver Clinic, Borland-Groover Clinic, P.A. Jacksonville, Florida
2008 - 2014 Chief of Gastroenterology, St. Vincent's Hospital Jacksonville, Florida
2002 – 2004 Ambulatory Care Physician, Outpatient Clinics Madrid, Spain
1991 – 1992 Ambulatory Care Physician, Outpatient Clinics Madrid, Spain

Medical Education

Medical Education
1985 – 1991 Doctor of Medicine Universidad Comlutense Madrid, Spain

Postgraduate Education

Postgraduate Education
2001 – 2002 Fellowship, Hepatology and Liver Transplantation Mayo Clinic Jacksonville Jacksonville, Florida
2001 – 1998 Fellowship, Gastroenterology University of Florida, Shands Jacksonville, Florida
1998 – 1995 Internship and Residency, Internal Medicine St. Lukes Hospital, University of Columbia St. Louis, Missouri

Professional Associations

  • AASLD – American Association for the Study of Liver Diseases
  • DCMS – Duval County Medical Society
  • Speaker Bureau for Schering Company
  • A Phase 2 Study of Telaprevir(VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With A Prior Course of Interferon-Based Therapy - Sub Investigator
  • A Roll Over Protcol of Telaprevir (VX-950)) In Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106 Who Do Not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response. - Sub Investigator
  • A Phase III Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®),and Ribavirin (Copegus®) in Treatment- Naïve Subjects With Genotype 1 Chronic Hepatitis C. - Sub Investigator
  • A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for The Induction of Remission In Subjects Experiencing Treatment-Refactory Moderate- to- Severe Crohn’s Disease. - Sub Investigator
  • A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment – Refactory Moderate- to Severe Crohn’s Disease. - Sub Investigator
  • A Randomized, Open Label, MulticenterStudy Examining the Effects of 24 Verses 48 Weeks of Combination Therapy With PEGASYS (Peginterferon alfa-2a-40 KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who Do Not Achieve A Rapid Viral Response. - Principal Investigator
  • A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety,Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults with Non- Alcoholic Steatohepatitis (NASH) - Principal Investigator
  • A Phase 3b, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects with Chronic Hepatitis B who are Resistant to Lamivudine - Principal Investigator
  • Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Eficacy (as measured by Sustained Virological Response) and Safety of 360  Induction Dosing of Pegasys® In Combination with Higher Copegus® Doses in Treatment- naïve Patients with Chronic Hepatitis C Genotype I Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg. - Principal Investigator
  • An open label trial of daily Interferon induction follow by combination ribavirin and daily high dose Interferon in HCV patients, A. Corregidor, J. Li, P. Ricci, L. Cubbedge, C.G. Bruno, L.R. Lambiase UFHSC., Jacksonville, Florida
  • Effect of alcohol intake on clinical, virological and pathological aspects in patients with Hepatitis C., A. Corregidor, C. Monteiro, L.R. Lambiase, L. Cubbedge, C. Fang, J. Munoz, J. Li, UFHSC., Jacksonville, Florida
  • Association of Liver Steatosis and Chronic Heaptitis C,. J. Li, A. Corregidor, C. Monteiro, L. Cubbedge, C. Fang, J. Munoz, L.R. Lambiase FHSC., Jacksonville, Florida